<!DOCTYPE html>
<html lang="en-US" dir="ltr">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <title>VitePress | VitePress</title>
    <meta name="description" content="A VitePress site">
    <link rel="preload stylesheet" href="/assets/style.32830522.css" as="style">
    
    <script type="module" src="/assets/app.a80b09b5.js"></script>
    <link rel="preload" href="/assets/inter-roman-latin.2ed14f66.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="modulepreload" href="/assets/chunks/framework.cc795e4d.js">
    <link rel="modulepreload" href="/assets/chunks/theme.e9da4b14.js">
    <link rel="modulepreload" href="/assets/docs_index.md.3b7fa955.lean.js">
    <script id="check-dark-mode">(()=>{const e=localStorage.getItem("vitepress-theme-appearance")||"auto",a=window.matchMedia("(prefers-color-scheme: dark)").matches;(!e||e==="auto"?a:e==="dark")&&document.documentElement.classList.add("dark")})();</script>
    <script id="check-mac-os">document.documentElement.classList.toggle("mac",/Mac|iPhone|iPod|iPad/i.test(navigator.platform));</script>
  </head>
  <body>
    <div id="app"><div class="Layout" data-v-9d8abc1e><!--[--><!--]--><!--[--><span tabindex="-1" data-v-c8291ffa></span><a href="#VPContent" class="VPSkipLink visually-hidden" data-v-c8291ffa> Skip to content </a><!--]--><!----><header class="VPNav" data-v-9d8abc1e data-v-7ad780c2><div class="VPNavBar top" data-v-7ad780c2 data-v-f1abbc6e><div class="container" data-v-f1abbc6e><div class="title" data-v-f1abbc6e><div class="VPNavBarTitle" data-v-f1abbc6e data-v-2973dbb4><a class="title" href="/" data-v-2973dbb4><!--[--><!--]--><!----><!--[-->VitePress<!--]--><!--[--><!--]--></a></div></div><div class="content" data-v-f1abbc6e><div class="curtain" data-v-f1abbc6e></div><div class="content-body" data-v-f1abbc6e><!--[--><!--]--><div class="VPNavBarSearch search" data-v-f1abbc6e><!----></div><!----><!----><div class="VPNavBarAppearance appearance" data-v-f1abbc6e data-v-283b26e9><button class="VPSwitch VPSwitchAppearance" type="button" role="switch" title="toggle dark mode" aria-checked="false" data-v-283b26e9 data-v-3329432d data-v-1c29e291><span class="check" data-v-1c29e291><span class="icon" data-v-1c29e291><!--[--><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" viewbox="0 0 24 24" class="sun" data-v-3329432d><path d="M12,18c-3.3,0-6-2.7-6-6s2.7-6,6-6s6,2.7,6,6S15.3,18,12,18zM12,8c-2.2,0-4,1.8-4,4c0,2.2,1.8,4,4,4c2.2,0,4-1.8,4-4C16,9.8,14.2,8,12,8z"></path><path d="M12,4c-0.6,0-1-0.4-1-1V1c0-0.6,0.4-1,1-1s1,0.4,1,1v2C13,3.6,12.6,4,12,4z"></path><path d="M12,24c-0.6,0-1-0.4-1-1v-2c0-0.6,0.4-1,1-1s1,0.4,1,1v2C13,23.6,12.6,24,12,24z"></path><path d="M5.6,6.6c-0.3,0-0.5-0.1-0.7-0.3L3.5,4.9c-0.4-0.4-0.4-1,0-1.4s1-0.4,1.4,0l1.4,1.4c0.4,0.4,0.4,1,0,1.4C6.2,6.5,5.9,6.6,5.6,6.6z"></path><path d="M19.8,20.8c-0.3,0-0.5-0.1-0.7-0.3l-1.4-1.4c-0.4-0.4-0.4-1,0-1.4s1-0.4,1.4,0l1.4,1.4c0.4,0.4,0.4,1,0,1.4C20.3,20.7,20,20.8,19.8,20.8z"></path><path d="M3,13H1c-0.6,0-1-0.4-1-1s0.4-1,1-1h2c0.6,0,1,0.4,1,1S3.6,13,3,13z"></path><path d="M23,13h-2c-0.6,0-1-0.4-1-1s0.4-1,1-1h2c0.6,0,1,0.4,1,1S23.6,13,23,13z"></path><path d="M4.2,20.8c-0.3,0-0.5-0.1-0.7-0.3c-0.4-0.4-0.4-1,0-1.4l1.4-1.4c0.4-0.4,1-0.4,1.4,0s0.4,1,0,1.4l-1.4,1.4C4.7,20.7,4.5,20.8,4.2,20.8z"></path><path d="M18.4,6.6c-0.3,0-0.5-0.1-0.7-0.3c-0.4-0.4-0.4-1,0-1.4l1.4-1.4c0.4-0.4,1-0.4,1.4,0s0.4,1,0,1.4l-1.4,1.4C18.9,6.5,18.6,6.6,18.4,6.6z"></path></svg><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" viewbox="0 0 24 24" class="moon" data-v-3329432d><path d="M12.1,22c-0.3,0-0.6,0-0.9,0c-5.5-0.5-9.5-5.4-9-10.9c0.4-4.8,4.2-8.6,9-9c0.4,0,0.8,0.2,1,0.5c0.2,0.3,0.2,0.8-0.1,1.1c-2,2.7-1.4,6.4,1.3,8.4c2.1,1.6,5,1.6,7.1,0c0.3-0.2,0.7-0.3,1.1-0.1c0.3,0.2,0.5,0.6,0.5,1c-0.2,2.7-1.5,5.1-3.6,6.8C16.6,21.2,14.4,22,12.1,22zM9.3,4.4c-2.9,1-5,3.6-5.2,6.8c-0.4,4.4,2.8,8.3,7.2,8.7c2.1,0.2,4.2-0.4,5.8-1.8c1.1-0.9,1.9-2.1,2.4-3.4c-2.5,0.9-5.3,0.5-7.5-1.1C9.2,11.4,8.1,7.7,9.3,4.4z"></path></svg><!--]--></span></span></button></div><!----><div class="VPFlyout VPNavBarExtra extra" data-v-f1abbc6e data-v-c8c2ae4b data-v-aa8de344><button type="button" class="button" aria-haspopup="true" aria-expanded="false" aria-label="extra navigation" data-v-aa8de344><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" viewbox="0 0 24 24" class="icon" data-v-aa8de344><circle cx="12" cy="12" r="2"></circle><circle cx="19" cy="12" r="2"></circle><circle cx="5" cy="12" r="2"></circle></svg></button><div class="menu" data-v-aa8de344><div class="VPMenu" data-v-aa8de344 data-v-e42ed9b3><!----><!--[--><!--[--><!----><div class="group" data-v-c8c2ae4b><div class="item appearance" data-v-c8c2ae4b><p class="label" data-v-c8c2ae4b>Appearance</p><div class="appearance-action" data-v-c8c2ae4b><button class="VPSwitch VPSwitchAppearance" type="button" role="switch" title="toggle dark mode" aria-checked="false" data-v-c8c2ae4b data-v-3329432d data-v-1c29e291><span class="check" data-v-1c29e291><span class="icon" data-v-1c29e291><!--[--><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" viewbox="0 0 24 24" class="sun" data-v-3329432d><path d="M12,18c-3.3,0-6-2.7-6-6s2.7-6,6-6s6,2.7,6,6S15.3,18,12,18zM12,8c-2.2,0-4,1.8-4,4c0,2.2,1.8,4,4,4c2.2,0,4-1.8,4-4C16,9.8,14.2,8,12,8z"></path><path d="M12,4c-0.6,0-1-0.4-1-1V1c0-0.6,0.4-1,1-1s1,0.4,1,1v2C13,3.6,12.6,4,12,4z"></path><path d="M12,24c-0.6,0-1-0.4-1-1v-2c0-0.6,0.4-1,1-1s1,0.4,1,1v2C13,23.6,12.6,24,12,24z"></path><path d="M5.6,6.6c-0.3,0-0.5-0.1-0.7-0.3L3.5,4.9c-0.4-0.4-0.4-1,0-1.4s1-0.4,1.4,0l1.4,1.4c0.4,0.4,0.4,1,0,1.4C6.2,6.5,5.9,6.6,5.6,6.6z"></path><path d="M19.8,20.8c-0.3,0-0.5-0.1-0.7-0.3l-1.4-1.4c-0.4-0.4-0.4-1,0-1.4s1-0.4,1.4,0l1.4,1.4c0.4,0.4,0.4,1,0,1.4C20.3,20.7,20,20.8,19.8,20.8z"></path><path d="M3,13H1c-0.6,0-1-0.4-1-1s0.4-1,1-1h2c0.6,0,1,0.4,1,1S3.6,13,3,13z"></path><path d="M23,13h-2c-0.6,0-1-0.4-1-1s0.4-1,1-1h2c0.6,0,1,0.4,1,1S23.6,13,23,13z"></path><path d="M4.2,20.8c-0.3,0-0.5-0.1-0.7-0.3c-0.4-0.4-0.4-1,0-1.4l1.4-1.4c0.4-0.4,1-0.4,1.4,0s0.4,1,0,1.4l-1.4,1.4C4.7,20.7,4.5,20.8,4.2,20.8z"></path><path d="M18.4,6.6c-0.3,0-0.5-0.1-0.7-0.3c-0.4-0.4-0.4-1,0-1.4l1.4-1.4c0.4-0.4,1-0.4,1.4,0s0.4,1,0,1.4l-1.4,1.4C18.9,6.5,18.6,6.6,18.4,6.6z"></path></svg><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" viewbox="0 0 24 24" class="moon" data-v-3329432d><path d="M12.1,22c-0.3,0-0.6,0-0.9,0c-5.5-0.5-9.5-5.4-9-10.9c0.4-4.8,4.2-8.6,9-9c0.4,0,0.8,0.2,1,0.5c0.2,0.3,0.2,0.8-0.1,1.1c-2,2.7-1.4,6.4,1.3,8.4c2.1,1.6,5,1.6,7.1,0c0.3-0.2,0.7-0.3,1.1-0.1c0.3,0.2,0.5,0.6,0.5,1c-0.2,2.7-1.5,5.1-3.6,6.8C16.6,21.2,14.4,22,12.1,22zM9.3,4.4c-2.9,1-5,3.6-5.2,6.8c-0.4,4.4,2.8,8.3,7.2,8.7c2.1,0.2,4.2-0.4,5.8-1.8c1.1-0.9,1.9-2.1,2.4-3.4c-2.5,0.9-5.3,0.5-7.5-1.1C9.2,11.4,8.1,7.7,9.3,4.4z"></path></svg><!--]--></span></span></button></div></div></div><!----><!--]--><!--]--></div></div></div><!--[--><!--]--><button type="button" class="VPNavBarHamburger hamburger" aria-label="mobile navigation" aria-expanded="false" aria-controls="VPNavScreen" data-v-f1abbc6e data-v-6bee1efd><span class="container" data-v-6bee1efd><span class="top" data-v-6bee1efd></span><span class="middle" data-v-6bee1efd></span><span class="bottom" data-v-6bee1efd></span></span></button></div></div></div></div><!----></header><!----><!----><div class="VPContent is-home" id="VPContent" data-v-9d8abc1e data-v-3cf691b6><div class="VPHome" data-v-3cf691b6 data-v-20eabd3a><!--[--><!--]--><div class="VPHero VPHomeHero" data-v-20eabd3a data-v-5a3e9999><div class="container" data-v-5a3e9999><div class="main" data-v-5a3e9999><!--[--><h1 class="name" data-v-5a3e9999><span class="clip" data-v-5a3e9999>2022年ADA简讯</span></h1><!----><p class="tagline" data-v-5a3e9999>一站式获得ADA前沿进展</p><!--]--><div class="actions" data-v-5a3e9999><!--[--><div class="action" data-v-5a3e9999><a class="VPButton medium brand" href="/ADA%20%E5%A5%96%E9%A1%B9/%E5%9B%BD%E5%AE%B6%E7%A7%91%E5%AD%A6%E5%92%8C%E5%8D%AB%E7%94%9F%E4%BF%9D%E5%81%A5%E6%88%90%E5%B0%B1%E5%A5%96/Banting%E7%A7%91%E5%AD%A6%E6%88%90%E5%B0%B1%E5%A5%96.html" data-v-5a3e9999 data-v-1e76fe75>让我们开始吧</a></div><!--]--></div></div><!----></div></div><!--[--><!--]--><!--[--><!--]--><div class="VPFeatures VPHomeFeatures" data-v-20eabd3a data-v-b1eea84a><div class="container" data-v-b1eea84a><div class="items" data-v-b1eea84a><!--[--><div class="grid-3 item" data-v-b1eea84a><a class="VPLink link no-icon VPFeature" href="/ADA%20%E5%A5%96%E9%A1%B9/%E5%9B%BD%E5%AE%B6%E7%A7%91%E5%AD%A6%E5%92%8C%E5%8D%AB%E7%94%9F%E4%BF%9D%E5%81%A5%E6%88%90%E5%B0%B1%E5%A5%96/Banting%E7%A7%91%E5%AD%A6%E6%88%90%E5%B0%B1%E5%A5%96.html" data-v-b1eea84a data-v-ee984185><!--[--><article class="box" data-v-ee984185><!----><h2 class="title" data-v-ee984185>ADA奖项</h2><p class="details" data-v-ee984185>汇总ADA大会的各大奖项进展</p><!----></article><!--]--></a></div><div class="grid-3 item" data-v-b1eea84a><a class="VPLink link no-icon VPFeature" href="/%E7%96%BE%E7%97%85%E8%BF%9B%E5%B1%95/%E8%82%A5%E8%83%96%E4%B8%93%E9%A2%98/SURMOUNT-1-%E5%AF%B9%E5%BD%93%E5%89%8D%E8%82%A5%E8%83%96%E6%B2%BB%E7%96%97%E6%A8%A1%E5%BC%8F%E7%9A%84%E5%90%AF%E7%A4%BA.html" data-v-b1eea84a data-v-ee984185><!--[--><article class="box" data-v-ee984185><!----><h2 class="title" data-v-ee984185>疾病进展专题</h2><p class="details" data-v-ee984185>汇总糖尿病、肥胖、NAFLD等疾病专题进展</p><!----></article><!--]--></a></div><div class="grid-3 item" data-v-b1eea84a><a class="VPLink link no-icon VPFeature" href="/%E6%B2%BB%E7%96%97%E8%BF%9B%E5%B1%95/%E8%82%A0%E4%BF%83%E6%BF%80%E7%B4%A0%E4%B8%93%E9%A2%98/%E5%BA%A6%E6%8B%89%E7%B3%96%E8%82%BD%E6%B2%BB%E7%96%972%E5%9E%8B%E7%B3%96%E5%B0%BF%E7%97%85-T2D-%E9%9D%92%E5%B0%91%E5%B9%B4%E6%82%A3%E8%80%85-AWARD-PEDS%E9%9A%8F%E6%9C%BA-%E5%AE%89%E6%85%B0%E5%89%82%E5%AF%B9%E7%85%A7%E8%AF%95%E9%AA%8C%E7%9A%84%E7%BB%93%E6%9E%9C.html" data-v-b1eea84a data-v-ee984185><!--[--><article class="box" data-v-ee984185><!----><h2 class="title" data-v-ee984185>治疗进展</h2><p class="details" data-v-ee984185>汇总当前糖尿病药物进展研究</p><!----></article><!--]--></a></div><!--]--></div></div></div><!--[--><!--]--><div style="position:relative;" data-v-20eabd3a><div></div></div></div></div><!----><!--[--><!--]--></div></div>
    <script>window.__VP_HASH_MAP__=JSON.parse("{\"docs_index.md\":\"3b7fa955\",\"docs_ada 奖项_国家科学和卫生保健成就奖_糖尿病杰出教育者奖.md\":\"99e47512\",\"docs_ada 奖项_ada专业委员会奖_edwinbierman奖.md\":\"56ee4a64\",\"docs_ada 奖项_国家科学和卫生保健成就奖_kellywest流行病学杰出成就奖.md\":\"9122b6f8\",\"docs_中国声音_智能胰岛素贴片等_20岁前新发2型糖尿病患者的心血管疾病-肾病和死亡发生率-香港全地区的8年随访监测.md\":\"4634b4ec\",\"docs_ada 奖项_国家科学和卫生保健成就奖_banting科学成就奖.md\":\"4074fe5a\",\"docs_治疗进展_肠促激素专题_应用新型gipglp-1胰高血糖素三受体激动剂ly3437943-ly-12周可改善t2dm患者血糖及体重.md\":\"698b90f7\",\"docs_中国声音_智能胰岛素贴片等_智能胰岛素贴片.md\":\"f66c1fa3\",\"docs_中国声音_智能胰岛素贴片等_homa2与2型糖尿病临床结局的相关性.md\":\"b6590bd1\",\"docs_治疗进展_其他治疗_糖尿病患者和照顾者使用胰高血糖素鼻喷剂的经验研究.md\":\"6e477863\",\"docs_疾病进展_1型糖尿病专题_cgm指标-hba1c和视网膜病变与长期1型糖尿病病程存在差异相关性.md\":\"2f15330c\",\"docs_糖尿病管理_2型糖尿病高血糖管理_2022版ada-easd-2型糖尿病高血糖管理共识-草案-.md\":\"e433d4b5\",\"docs_糖尿病管理_低血糖管理_低血糖-cgm指标和hba1c--医生观点.md\":\"96ef3408\",\"docs_疾病进展_肥胖专题_药物治疗在糖尿病和肥胖治疗中的作用-一种新的治疗模式-将持续减肥作为2型糖尿病的治疗.md\":\"7102182c\",\"docs_疾病进展_肥胖专题_surmount-1-对当前肥胖治疗模式的启示.md\":\"f46b7a55\",\"docs_治疗进展_肠促激素专题_在心血管风险增加的2型糖尿病患者中-tirzepatide与甘精胰岛素相比对hba1c控制的持续性-surpass-4-.md\":\"51963c84\",\"docs_糖尿病管理_并发症管理_糖尿病大血管病变_glp1-ra-而非sglt2i-应作为糖尿病患者缺血性卒中预防的首选抗糖尿病治疗.md\":\"7962c681\",\"docs_中国声音_智能胰岛素贴片等_2型糖尿病代谢综合征的诊断中-腰围-身高比是比腰围更好的指标.md\":\"c0280f5b\",\"docs_中国声音_智能胰岛素贴片等_血糖时间序列复杂性与2型糖尿病患者全因死亡率之间的相关性-一项前瞻性队列研究.md\":\"ac4f627f\",\"docs_治疗进展_肠促激素专题_与选择性glp-1受体激动剂相比-tirzepatide对每单位体重减轻的胰岛素敏感性改善更大.md\":\"78d441f7\",\"docs_疾病进展_1型糖尿病专题_急性低血糖对1型糖尿病成人患者认知功能影响的系统综述和荟萃分析.md\":\"859a9b44\",\"docs_糖尿病管理_并发症管理_糖尿病大血管病变_rewind中与度拉糖肽和心血管事件相关的蛋白质生物标志物.md\":\"566244c2\",\"docs_糖尿病管理_低血糖管理_单一低血糖事件导致免疫应答延长.md\":\"43b547c3\",\"docs_ada 奖项_国家科学和卫生保健成就奖_杰出的科学成就奖.md\":\"9faeb5ac\",\"docs_治疗进展_肠促激素专题_在2型糖尿病患者中-与司美格鲁肽相比-tirzepatide改善了胰岛细胞功能-空腹胰高血糖素和homa2-b-和胰岛素敏感性-空腹胰岛素和homa2-ir-的标志物.md\":\"8b143af6\",\"docs_ada 奖项_ada专业委员会奖_norbertfreinkel奖.md\":\"d3b1c94e\",\"docs_疾病进展_糖尿病机制研究_-正常-体重人群减肥后2型糖尿病的缓解-retune研究.md\":\"7ac6a8da\",\"docs_疾病进展_nafld专题_糖尿病-血脂学中的nash及其诊断.md\":\"7c194d2d\",\"docs_疾病进展_糖尿病机制研究_减少脂肪酸氧化可预防intralipid诱导的人肝脏胰岛素抵抗.md\":\"c5e87365\",\"docs_治疗进展_胰岛素专题_在主要为中国2型糖尿病-t2d-成人患者中-超快速赖脯胰岛素-urli-相较于优泌乐-hl-改善餐后血糖-ppg-波动.md\":\"1b0fbfa4\",\"docs_疾病进展_nafld专题_nafld的新兴疗法有哪些.md\":\"a3b81b61\",\"docs_治疗进展_胰岛素专题_在胰岛素初治的2型糖尿病-t2d-患者中-每周一次基础胰岛素bif的血糖控制与每日一次德谷胰岛素-deg-相似.md\":\"0b52d39c\",\"docs_疾病进展_糖尿病机制研究_天然ldl上调人脂肪组织中nlrp3炎症小体-高apob受试者2型糖尿病高风险的机制.md\":\"aaafbc8d\",\"docs_糖尿病管理_并发症管理_糖尿病大血管病变_年轻成人糖尿病患者动脉僵硬度升高与心脏靶器官损伤的相关性-青少年糖尿病研究.md\":\"ae25d1b4\",\"docs_治疗进展_肠促激素专题_度拉糖肽治疗2型糖尿病-t2d-青少年患者-award-peds随机-安慰剂对照试验的结果.md\":\"51805f94\",\"docs_糖尿病管理_并发症管理_糖尿病肾病_共识-ada和kdigo关于糖尿病和ckd管理的新联合声明.md\":\"c20ef2a9\",\"docs_疾病进展_肥胖专题_surmount-1-gip-glp-1受体激动剂tirzepatide在肥胖适应症的3期临床研究-.md\":\"6a84f7c2\",\"docs_糖尿病管理_并发症管理_糖尿病肾病_dkd试验中肾脏终点的选择-硬性肾脏结局或经过验证的替代指标-.md\":\"ffe8110d\",\"docs_糖尿病管理_并发症管理_糖尿病肾病_在surpass-4研究中-tirzepatide与甘精胰岛素100u-ml对2糖尿病受试者肾脏结局的影响-ada大会主席的荐选摘要-.md\":\"bea452b6\",\"docs_糖尿病管理_并发症管理_糖尿病肾病_ckd和t2d患者中按应用glp-1ra情况分组观查finerenone的作用.md\":\"2d842857\",\"docs_糖尿病管理_生活方式干预_lookahead研究中-中度至剧烈体力活动的时间与2型糖尿病血糖控制改善相关.md\":\"a61159f0\"}");window.__VP_SITE_DATA__=JSON.parse("{\"lang\":\"en-US\",\"dir\":\"ltr\",\"title\":\"VitePress\",\"description\":\"A VitePress site\",\"base\":\"/\",\"head\":[],\"appearance\":true,\"themeConfig\":{},\"locales\":{},\"scrollOffset\":90,\"cleanUrls\":false}");</script>
    
  </body>
</html>